About Us About Us

Management Team

The drug development process is complex. Our management team offers deep expertise in all aspects of the process to drive products toward commercialization.


David Mims

David W. Mims

Interim CEO

David W. Mims joined our Board and was appointed Interim CEO November 2019. Mr. Mims has served as a member of the board of directors at each of Guideway Care, a healthcare company that provides technology-enabled care guidance, since May 2017 and SouthPoint Bank, a community banking institution, since August 2015. Previously, Mr. Mims served as President, U.S. Specialty Pharmaceuticals for Aptalis Pharma Inc. (“Aptalis”) (f/k/a Axcan Pharma Inc.), a privately held pharmaceutical company, from May 2011 until May 2014, shortly after it was acquired by Forest Laboratories, Inc. (formerly NYSE: FRX). While at Aptalis, Mr. Mims managed over 200 employees and grew the business to over $475 million in annual net sales. Mr. Mims similarly served as President, U.S. Specialty Pharmaceuticals at Axcan Intermediate Holdings Inc., the parent company of Axcan Pharma Inc. (formerly TSE: AXP and NASDAQ: AXCA), from February 2008 until May 2014 and as a member on its board from 2000 to 2007. Mr. Mims began working at Axcan Pharma Inc. as Executive Vice President and Chief Operating Officer in 2000 after the company acquired Scandipharm, Inc., a privately held pharmaceutical company, which Mr. Mims helped found and for which he served as Vice President, Chief Operating Officer and Chief Financial Officer, from 1991 until 1998. During his career as a pharmaceutical executive, Mr. Mims has played a significant role in raising over $1 billion in capital and successfully leading multiple commercial organizations including the new product launches. Mr. Mims was also an integral part of multiple transactions, including the sale of Scandipharm to Axcan Pharma, Inc. for ~$100 million, the sale of Axcan Pharma, Inc. to TPG Capital for $1.3 billion, the acquisition of Eurand, Inc. for $583 million and the sale of Aptalis to Forest Laboratories for $2.9 billion. Currently, Mr. Mims serves as a member of the American Institute of Certified Public Accountants and Alabama Society of Certified Public Accountants. Previously, Mr. Mims served as a director of the University of Alabama at Birmingham Research Foundation. Mr. Mims is a licensed CPA (inactive). Mr. Mims received his B.S. in accounting from Auburn University.


Asha Das, MD

Chief Medical Officer

Dr. Das joined the Company in 2019 as Chief Medical Officer. Prior to joining Progenics, she was Chief Medical Officer at Tocagen, a publicly traded biotechnology company with a cancer-selective gene therapy platform. Previously, Dr. Das was at Genentech, a member of the Roche Group, most recently as Group Medical Director. She was responsible for leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to TECENTRIQ®. Dr. Das also served as Associate Medical Director at Eisai Inc., a pharmaceutical company, where she focused on clinical activities related to the oncology therapeutics HALAVEN® and LENVIMA™. Prior to that, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center.

Dr. Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology by the United Council for Neurologic Subspecialties and previously served as a clinical fellow in neuro-oncology at Massachusetts General Hospital. Dr. Das completed her residency in neurology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. Dr. Das obtained her medical degree from Weill Cornell Medical College and bachelor’s degree from Cornell University.


v_wong

Pat Fabbio

Executive Vice President and Chief Financial Officer

Mr. Fabbio joined the Company in November 2015 and currently serves as Executive Vice President and Chief Financial Officer. Prior to Progenics, he was Chief Financial Officer of electroCore, a privately-held bioelectric medicine healthcare company, and Vice President, Finance for NPS Pharmaceuticals, Inc., a publicly traded, global rare disease company that was acquired by Shire. Mr. Fabbio has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies including: Vice President, Finance, Catalent Pharma Solutions; Chief Financial Officer of Ikano Therapeutics; senior corporate finance, commercial, and transactional roles at Sanofi; and Corporate Controller for Biomatrix Inc., a publicly traded biotechnology company that was acquired by Genzyme. He graduated from Pace University with a B.B.A. in Accounting and from the Stern School of Business at New York University, with a Master’s Degree in Finance. He received his certified public accountant license in New Jersey.


Benedict Osorio

Benedict Osorio

Chief Operating Officer

Mr. Osorio joined the Company in 2018 and currently serves as Chief Operating Officer. He has over three decades of experience in pharmaceutical quality control and quality assurance, including service as Vice President, Quality Assurance at Acorda Therapeutics, Vice President, Quality Assurance at Achillion Pharmaceuticals, Vice President, Quality Operations North America at Valeant Pharmaceuticals, Global Head of Quality for Braeburn Pharmaceuticals, Senior Consultant at Complya Consulting, Vice President and Senior Vice President, Quality at Progenics Pharmaceuticals, Director and Senior Director at Forest Laboratories, various positions of increasing responsibility with The PF Laboratories (a subsidiary of Purdue Pharma), ultimately as Executive Director, Quality Assurance and analytical chemist with Berlex Laboratories. He earned both an M.B.A. and an M.S. in chemistry from Seton Hall University and a B.S. in forensic Science from John Jay College of Criminal Justice.


v_wong

Vivien Wong, PhD

Executive Vice President, Development

Dr. Wong joined the Company in September 2007 and currently serves as Executive Vice President, Development. For three years prior to joining Progenics, Dr. Wong was Principal at Theritas Pharmaceutical Consultants. From 1989 to 2004, she held positions of increasing responsibility in preclinical development and pharmacology at Emisphere Technologies, Vivoquest, and Regeneron Pharmaceuticals. Dr. Wong has been a co-author on over 30 scientific articles for peer-reviewed journals. She received a B.Sc. in biology from the Mississippi University for Women, a PhD in anatomy and neurobiology from the University of Maryland School of Medicine, and completed a postdoctoral fellowship in neurology at the Albert Einstein College of Medicine.


Aseem Anand

Aseem Anand, PhD

Vice President, Digital Technology

Dr. Anand joined the Progenics in 2017 and is currently Vice President of Digital Technology. He has over 10 years of experience in clinical and regulatory development of novel biomarkers and medical devices. Prior to Progenics, Dr. Anand was a clinical research manager at Memorial Sloan Kettering Cancer Center (MSK) in the department of Medicine. At MSK, he initiated and led the translational science program to advance clinical research in patients with metastatic prostate cancer. Dr. Anand received his PhD in translational medicine from Lund University, Sweden and his Masters of Science from Columbia University, New York.


Jessica Jensen

Jessica Jensen, MPH

Senior Vice President, Clinical Development

Ms. Jensen joined the Company in 2014 and is currently Senior Vice President of Clinical Development. From 2014 to 2016, she held positions of increasing responsibility in Progenics across clinical operations, program management, and clinical development. She is a multi-disciplined and dynamic leader, with over 10 years of oncology research experience across all development phases. Prior to joining Progenics, Jessica advanced immunotherapy programs at the Ludwig Institute for Cancer Research where she led global clinical trials of combination therapies with immune checkpoint inhibitors and cancer vaccines. Prior thereto, Jessica led clinical operations for an orphan drug program at Gentium SpA, a biopharmaceutical company since acquired by Jazz Pharmaceuticals, and supported client programs as well as development of a contract research organization business unit at US Oncology. Jessica began her career in Statistical Programming and Biostatistics after receiving a Master of Public Health degree in Epidemiology & Biostatistics from the George Washington University.


Bryce Tenbarge

Bryce Tenbarge

Senior Vice President, Commercial

Mr. Tenbarge joined the Company in August 2016 and is currently Senior Vice President, Commercial. Prior to joining Progenics, he was Vice President of Marketing and Commercialization at Celldex Therapeutics, a publicly traded biotechnology company. Mr. Tenbarge has more than 15 years of commercial leadership experience with highly specialized products including: Senior Director of Global Oncology Marketing at Teva Pharmaceuticals and a variety of roles of increasing responsibility at Bristol-Myers Squibb in professional and payer marketing, market research and business intelligence. Mr. Tenbarge started his career as a commodity trader at Archer Daniels Midland in Chicago prior to receiving his MBA from The Ross School of Business at the University of Michigan.